 Peel Hunt reckons that clinical progress and data will be the catalyst for shares in Silence Therapeutics PLC AIM:SLN, NASDAQ:SLN, OTC:SLNCF in the next stage of its market journey. The drug developer, a specialist in precision medicines using gene silencing, used its third-quarter results to confirm the last day of trading on AIM will be November 29. 